Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

440 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ramipril and the development of diabetes.
Yusuf S, Gerstein H, Hoogwerf B, Pogue J, Bosch J, Wolffenbuttel BH, Zinman B; HOPE Study Investigators. Yusuf S, et al. JAMA. 2001 Oct 17;286(15):1882-5. doi: 10.1001/jama.286.15.1882. JAMA. 2001. PMID: 11597291 Clinical Trial.
Effect of ramipril on the incidence of diabetes.
DREAM Trial Investigators; Bosch J, Yusuf S, Gerstein HC, Pogue J, Sheridan P, Dagenais G, Diaz R, Avezum A, Lanas F, Probstfield J, Fodor G, Holman RR. DREAM Trial Investigators, et al. Among authors: gerstein hc. N Engl J Med. 2006 Oct 12;355(15):1551-62. doi: 10.1056/NEJMoa065061. Epub 2006 Sep 15. N Engl J Med. 2006. PMID: 16980380 Free article. Clinical Trial.
Treatment satisfaction and quality of life using an early insulinization strategy with insulin glargine compared to an adjusted oral therapy in the management of Type 2 diabetes: the Canadian INSIGHT Study.
Houlden R, Ross S, Harris S, Yale JF, Sauriol L, Gerstein HC. Houlden R, et al. Among authors: gerstein hc. Diabetes Res Clin Pract. 2007 Nov;78(2):254-8. doi: 10.1016/j.diabres.2007.03.021. Epub 2007 May 9. Diabetes Res Clin Pract. 2007. PMID: 17490781 Clinical Trial.
Effect of Rosiglitazone and Ramipril on {beta}-cell function in people with impaired glucose tolerance or impaired fasting glucose: the DREAM trial.
Hanley AJ, Zinman B, Sheridan P, Yusuf S, Gerstein HC; Diabetes Reduction Assessment With Ramipril and Rosiglitazone Medication (DREAM) Investigators. Hanley AJ, et al. Among authors: gerstein hc. Diabetes Care. 2010 Mar;33(3):608-13. doi: 10.2337/dc09-1579. Epub 2009 Dec 15. Diabetes Care. 2010. PMID: 20009095 Free PMC article. Clinical Trial.
Effect of rosiglitazone on progression of coronary atherosclerosis in patients with type 2 diabetes mellitus and coronary artery disease: the assessment on the prevention of progression by rosiglitazone on atherosclerosis in diabetes patients with cardiovascular history trial.
Gerstein HC, Ratner RE, Cannon CP, Serruys PW, García-García HM, van Es GA, Kolatkar NS, Kravitz BG, Miller DM, Huang C, Fitzgerald PJ, Nesto RW; APPROACH Study Group. Gerstein HC, et al. Circulation. 2010 Mar 16;121(10):1176-87. doi: 10.1161/CIRCULATIONAHA.109.881003. Epub 2010 Mar 1. Circulation. 2010. PMID: 20194881 Clinical Trial.
Treatment gaps in the management of cardiovascular risk factors in patients with type 2 diabetes in Canada.
Braga M, Casanova A, Teoh H, Dawson KC, Gerstein HC, Fitchett DH, Harris SB, Honos G, McFarlane PA, Steele A, Ur E, Yale JF, Langer A, Goodman SG, Leiter LA; Diabetes Registry to Improve Vascular Events (DRIVE) Investigators. Braga M, et al. Among authors: gerstein hc. Can J Cardiol. 2010 Jun-Jul;26(6):297-302. doi: 10.1016/s0828-282x(10)70393-7. Can J Cardiol. 2010. PMID: 20548975 Free PMC article.
440 results